key: cord-0040633-lgswllrw
authors: Evermann, James F.; Wills, Tamara B.
title: Immunologic Development and Immunization
date: 2010-09-02
journal: Small Animal Pediatrics
DOI: 10.1016/b978-1-4160-4889-3.00014-0
sha: 2b5b4fe30aaed10fbed8e9b7baea09f3f73ef0d1
doc_id: 40633
cord_uid: lgswllrw

nan

Development and function of complement pathways, antigen-presenting cells (APCs), phagocytic cells, and other pathways of the innate immune system have not been well characterized in puppies. However, one study observed increased phagocytic activity of neutrophils and macrophages in neonatal puppies compared to young adult dogs, suggesting there may be adequate function of phagocytic cells in puppies to help with the first line of defense against potential pathogens. In humans and mice, APCs have reduced ligand expression, which is necessary for stimulating specific immune responses, compared to adults. Although this has not been specifically evaluated in dogs, APCs may not be mature in neonatal puppies.

Immunologic development of the lymphoid system is incremental in all species. As a generality, the shorter the gestation, the less developed the immune system is at birth.

The immune response is essential for survival from the wide array of infectious microorganisms to which the puppy and kitten are exposed. The immune responses of neonates are inferior to those of mature dogs and cats, not because components of the immune system are lacking, but because the soluble mediators are present in suboptimal concentration and cellular elements are in a naive state.

The transition from a protected environment in the uterus to an environment containing a variety of potential infectious agents requires a rapid response by the immune system to protect the neonate from infections. Many factors play a role in the newborn's survival, including its innate immune system, acquired immune system, and passive transfer of maternal antibodies. Other factors, such as the dam or queen's health, nutrition status, immunization status, parasitic control, breeding management, and environment, also have an impact on health, sickness, or survival of the neonate. Understanding immunologic development of the newborn is necessary to recognize the role of immune protection from birth to 12 months, the role of maternal antibody in early immune protection, as well as the response and effect of vaccination at an early age.

In general, innate immunity is a rapid, nonspecific first line of defense. Neutrophils, macrophages, and natural killer lymphocytes are the first responders, whereas cellular products such as complement and cytokines also play a role in innate immunity. Barriers, such as skin and mucosa, and normal bacterial flora are other components of innate immunity. Acquired immunity is a slower, but a specific second line of defense involving B lymphocytes, T-helper (Th) lymphocytes (CD4+ cells), and T cytotoxic lymphocytes (CD8+ cells). Acquired immunity is further broken down into steadily with age, whereas CD4+ T lymphocytes maintain at relatively steady numbers from birth to adulthood.

Knowledge of the distribution of peripheral lymphocytes is important to help determine if there are areas of immune deficiency in the neonate; however, function is another defining characteristic. Functional lymphocytes have been observed in the fetus, which is able to respond to antigens after lymphoid tissue develops in the last third of gestation. However, the antibody responses are variable and not as pronounced when compared to adults. Functional and specific lymphocyte responses are also present at birth, but similar to the fetus, antibody responses are often only a portion of the adult antibody response. One study observed adequate antibody response in day-old puppies immunized with a modified live canine parvovirus strain, suggesting some antigens may elicit an adequate antibody response, or some puppies have a higher level of immune development. In general, it is recognized that domestic animals are immunocompetent at birth; however, complete maturation of the immune system occurs postnatally.

Development of the kitten's first line of defense, the innate immune system, including complement pathways, APCs, and other pathways of the innate immune system has not been well described. Neutrophil function has been evaluated, and phagocytic function is present at birth to help combat initial potential pathogens but is only a portion of adult response. The observed phagocytic response is independent In puppies, immunologic development is an early event, beginning in midgestation with lymphocytes present in circulation at 25 days of gestation (Figure 14-1) . Thymic development begins on day 27 of gestation, followed by lymphoid infiltration into secondary lymphoid organs, including spleen and lymph nodes, on days 45 to 52 of gestation. Thymic development appears histologically normal by day 45 of gestation. In contrast, splenic and lymph node architecture is not completely developed in the fetus and lacks germinal centers and B cell follicles until shortly after birth.

At birth the numbers of peripheral lymphocytes increase and are initially composed of primarily B cells and CD4+ T cells with lower numbers of CD8+ T cytotoxic lymphocytes. The majority of T cells, almost 90%, are naive at birth compared to only 40% at 4 months of age, indicating progressive maturation of the T cell population during this time. The number of B lymphocytes in neonates is much higher than adults, but after the initial increase, B cell lymphocyte numbers decline until 16 weeks of age. The high proportion of B lymphocytes in newborns likely represents early B cell stimulation and maturation in response to new antigens. T cytotoxic lymphocytes are important in cell-mediated immunity and are low at birth. This finding may lend support to human and mouse studies showing downregulation of cell-mediated immunity in neonates. Because T cytotoxic lymphocytes are important for detecting and inactivating intracellular pathogens, the low numbers of T cytotoxic lymphocytes at birth may predispose a newborn to intracellular viral or bacterial infections. T cytotoxic lymphocytes increase nance of humoral immunity during pregnancy and immediately postpartum. This phenomenon of the Th cell populations is referred to as the "Th1-Th2 shift of pregnancy" and is generally regarded as a contributing factor to maternal tolerance of the fetus by suppressing the antifetal CMI response. The second key cell population affected during pregnancy and in the postpartum period is the neutrophil. The point of maximum immunosuppression occurs in the latter stages of pregnancy when there is an acute elevation in glucocorticoids. Neutrophil dysfunction and the effects on the Th cell population are considered temporary during this period. Nonetheless, with impaired neutrophil response, the animal is now vulnerable to increased bacterial infections caused by the compromised bactericidal functions.

The outcomes of the temporary immunodeficiency states allow for fetal survival but may also result in an increased susceptibility to environmental infections by bacteria and fungi. Intracellular infections, such as viruses and protozoans, which may have been acquired during postnatal development, may become exacerbated during pregnancy because of the suppressive effects on the Th1 cells. This suppression results in a decreased CMI response. The CMI effector cells, the T cytotoxic lymphocytes, function normally to control virtually all the viral infections such as canine herpesvirus. Intracellular bacterial infections, such as Brucella canis, become more pathogenic during pregnancy. In addition to the aforementioned effects on T cell function, macrophage function is also compromised, allowing opportunistic bacteria, which are usually confined to external mucosal surfaces of the body, to become systemic. Concurrent with the immunosuppression that accompanies pregnancy, there is an increased shedding of infectious microorganisms. This is considered to be an extension of impaired T cytotoxic lymphocyte function. Although the pregnant animal may appear clinically normal, her altered immune response results in an increased shedding of gastrointestinal viruses, such as canine coronavirus and canine rotavirus, and bacteria, such as Escherichia coli, usually during the periparturient period. This increase in shedding of infectious microorganisms is an important factor when addressing the issues of management of animals through this period of time ( Figure 14 -2). The suppression of neutrophil functions during later stages of pregnancy and immediately postpartum are the subject of active investigation.

Although the immunosuppressive periods during pregnancy and up to 4 weeks postpartum is well recognized, our understanding of this process is still somewhat rudimentary. However, we can proceed with control measures that accomplish two primary goals: to maximize reproductive performance and to assure successful neonatal survival. Over the years, we have emphasized the importance of effective vaccination programs prebreeding, clean birthing areas, and good hygiene for the lactating animal. In conjunction with good colostral management, these measures allow us to compensate for the temporary immunosuppressive states encountered during pregnancy and immediately thereafter. of colostrum ingestion and matures to an adult response by 8 weeks of age. Based on human and mouse studies, it is speculated that APCs may also have reduced function in kittens; however, this hypothesis requires further evaluation.

Unlike the dog, there are only a few studies published discussing lymphoid development from the fetus to six months of age in kittens. Similar to the dog, lymphocytes have been detected in fetal circulation at approximately 25 days of gestation. Lymphocytes have also been detected in the thymus, spleen, and liver at between 28 to 52 days of gestation supporting fetal development of lymphoid tissue. In late gestation, there is a significant increase in peripheral T lymphocytes, which remain elevated after birth becoming the primary circulating lymphocyte in the adult. CD4+ T lymphocytes are present in higher numbers than CD8+ T lymphocytes, resulting in a high CD4:CD8 ratio at birth. The low numbers of CD8+ T lymphocytes at birth may be an effect of the queen's immune status during pregnancy downregulating cell-mediated immunity, although this has not been evaluated in cats. CD8+ T lymphocytes begin to increase through 8 weeks of age, lowering the CD4+:CD8+ ratio. B cell numbers increase right after birth until 4 weeks of age, likely representative of maturation of the humoral immune response, then steadily decrease to adult values. The timeline for reaching adult distribution of lymphocyte subsets has not been definitively established but is thought to occur before 12 months of age. Similar to the puppy, kittens are immunocompetent at birth but appear to have restricted immune responses compared to adults. Antigenic stimulation of the fetus has not been documented in kittens so conclusions about fetal response to antigens are unknown.

The areas of maternal immunity pertaining to pregnancy, fetal survival, and postpartum periods have been the subject of active investigation. In its broadest context, the immune response of the pregnant dam and queen becomes compromised as the fetus matures. Although this immunodeficient state is transitory, it is now considered to extend through the postpartum period for up to 4 weeks.

The cellular mechanisms responsible for the pregnancy and postpartum immunosuppression are considered to revolve around two key cell populations. These involve the shift of T-helper cells from a Th1 to a Th2 response and a decrease in neutrophil functions. The T cell populations are affected by progesterone, prostaglandin F 2α , and α-fetoprotein. The Th1 cells are important effectors of the cell-mediated immune (CMI) response and interact with T cytotoxic lymphocytes. As mentioned earlier, the T cytotoxic lymphocytes are the main defense against intracellular pathogens. With the onset of pregnancy, the hormonal factors cause macrophages to release predominantly Th2stimulating cytokines that contribute to the overall domi-lacteals, and into the circulation. Immunity from colostrum depends on the vaccination and immune status of the dam, as well as the quantity of colostrum ingested. The amount of colostral antibody can be quite variable between littermates, depending on the amount of colostrum ingested, the time ingested, and the size of the litter.

Colostrum is composed of immunoglobulins, and in some species, such as cows, there are also numerous lymphocytes and proteins. Little information has been published about leukocytes or other proteins in canine colostrum, but some cellular material is transferred from the dam to the puppy. In dogs, IgG predominates in colostrum with slightly less IgA and very little immunoglobulin M (IgM). The peak immunoglobulin concentration in puppies ingesting colostrum is 12 to 24 hours after birth. Once colostrum transitions to milk, the concentrations of immunoglobulin significantly decrease in milk. The predominance of IgG in colostrum switches to a predominance of IgA in milk with only low levels of IgM and IgG detected at 6 weeks of lactation. This form of passive immunity is referred to as lactogenic immunity. The IgA has been shown to inhibit adherence of infectious agents to mucosal surfaces, neutralizing potential intestinal mucosal pathogens. Maternal antibody helps protect the neonate puppy but will also cause a refractory period to vaccination until maternal antibody declines.

Passive immunity from maternal antibodies is a vital component of immune protection to help prevent disease in neonates. In comparison to humans in which a significant amount of immunoglobulins are transferred transplacentally, dogs have an endotheliochorial placenta with four layers separating fetal and maternal blood. This type of placentation results in very little maternal immunoglobulin transfer to the fetus, with reported transplacental immunoglobulin transfer ranging from 5% to 10%. Colostrum is important for early antibody protection in puppies. In puppies, only small amounts of immunoglobulin G (IgG) are detected before colostrum ingestion and immunoglobulin A (IgA) is undetectable until after colostrum intake, supporting poor transplacental transfer. In mammals, intestinal permeability for immunoglobulin absorption is highest right after birth and decreases by 6 hours to a very low level of absorption 24 hours after birth. A low level of intestinal absorption of immunoglobulins continues while the puppy is nursing. Specific receptors in the intestine bind the immunoglobulin, which is then taken up by epithelial cells, transferred into competence and adequate response to vaccination or natural antigens depends on the concentration of colostral immunoglobulin ingested, as well as progressive development of the immune system.

Passive immunity is also important in the kitten for early immune protection. Like the dog, placentation is endotheliochorial, which means very little immunoglobulin is transferred from the queen to the fetus during pregnancy. The concentration of immunoprotective immunoglobulins in colostrum depends on the queen's immune and vaccination status, as well as the amount and timing of colostral ingestion. Similar to dogs, there can be variation of immunoglobulin ingestion within the same litter and between different litters from the same queen. At parturition, kittens have no IgG and little to no IgA before colostrum ingestion. Feline colostral IgG is very concentrated, almost 4.5 times the concentration of the queen's serum levels, and colostral IgA is present in much lower Endogenous immunoglobulin secretion will only be stimulated when maternal antibody decreases to a low level. Between 6 and 16 weeks, maternal antibody declines to undetectable limits and depends on the half-life of maternal canine immunoglobulin, which is approximately 8.4 days (Table 14-1). Loss of immunoglobulins is also dependent on antibody class with IgA degraded first, followed by IgM, and then IgG. Rapidly growing breeds have also been shown to break down maternally derived immunoglobulin at a faster rate. As maternal antibody decreases, endogenous immunoglobulin secretion steadily increases. The immunoglobulins tend to increase in order from IgM to IgG followed by IgA. These immunoglobulins reach adult levels at 2 to 3 months, 6 to 9 months, and 12 months, respectively.

Although maternal antibody is necessary for early protection in the neonate, it can be problematic as the puppy gets older by interfering with vaccine-induced immunity and the ability to respond to new antigens. As maternal antibody is decreasing, there is a window in which maternal immunoglobulin may decrease below protective levels but persist at high enough levels to interfere with vaccination and protective immune responses. This dangerous window is one reason that multiple vaccines are given close together in puppies less than 16 weeks of age to stimulate the immune system at the earliest time possible before exposure of antigen. It is important to know if the puppy has received colostrum because vaccination guidelines will differ, depending on whether colostrum was ingested. Puppies not receiving colostrum can elicit an adequate antibody response much sooner than puppies with maternal passive immunity ( Figure  14-3) .

In general, puppies begin life with a competent but immature immune system that matures over the first 6 to 12 months of life. The time frame of complete immuno- development of splenic architecture with APCs, such as macrophages and B cells, developing later than T cells. Additionally B cells, which are also APCs, have decreased expression of receptors and ligands, leading to less crosstalk between B lymphocytes and T lymphocytes compared to the adult, resulting in a blunted antibody response. Some of these factors are contributors to a shift toward the humoralmediated immune response, as well as a blunted immune response. In addition to the immaturity of the immune system, maternal antibody interferes with endogenous production of immunoglobulins, as well as response to vaccine antigens until 6 to 16 weeks of age. The immune response of puppies and kittens will always be variable due to differences in immune development, maternal antibody, antigen load, or route of vaccination. Taking into account differences in the immune system of the neonatal puppy or kitten will help determine future vaccination guidelines. Further characterization of the predominant immune system in neonates may be beneficial for developing new vaccinations to promote a balanced immune response. A balanced immune response will stimulate both the cellmediated and humoral immune-mediated responses to help prevent pathologic inflammation or hypersensitivity that can occur when only one side of the immune system is stimulated.

Since the duration of protection provided to puppies by maternal antibodies varies 5 weeks for canine coronavirus (CCV) to 20 weeks for canine distemper virus (CDV), it is recommended that puppies be vaccinated until active immunization occurs. Newer vaccines have proven to be effective in overcoming maternal antibodies and effectively stimulating the immune response as early as 12 weeks of age. Table  14 -2 provides a list of immunogens and a time frame for administration. Once the puppy series has been completed, a booster at 1 year of age is recommended. Subsequent boosters can be administered at annual, biannual, or triennial periods, depending on the risk of subsequent infection.

Kittens become susceptible to infectious disease once they begin to lose passive protection provided by the queen's colostrum. The length of this protection varies from 3 weeks for feline coronavirus (FCoV) to 15 weeks for feline panleukopenia (FPL) virus. Table 14-3 presents a list of immunogens and time for administration for kittens. The initial vaccination is given at 8 to 10 weeks of age and a booster at 14 to 16 weeks of age. A booster is recommended at 1 year of age. Subsequent boosters on an annual, biannual, or triennial basis are given according to the risk.

There has been increased emphasis on maternal vaccination for protection of puppies and kittens from infectious diseases. Box 14-1 lists the reasons to maintain an active immunization program. The latter three points pertain specifically to the beneficial effects of maternal vaccination. These include those already mentioned (stimulation of high levels of protective immunoglobulins in the colostrum and early milk), fetal protection from congenital infection, and decreased shedding of infectious microorganisms from subclinical carriers.

concentrations than IgG. Absorption of immunoglobulins in the intestine is similar in all mammals with the highest permeability occurring right after birth and very little immunoglobulin absorption by 24 hours after birth. Peak serum concentration of immunoglobulin occurs 1 to 2 days after parturition with low levels of immunoglobulin absorbed during the nursing period. As colostrum transitions to milk, there is a rapid decline of IgG concentration through day 7, which then remains the same for approximately 6 weeks. IgA levels remained steady throughout lactation. In contrast to dogs, feline milk is dominated by IgG rather than IgA.

Similar to all species, maternal antibody suppresses endogenous secretion of immunoglobulin until it decreases to low concentrations. Maternal immunoglobulin has an approximate half-life of 4.4 days, and maternal antibody can be undetectable in some kittens by 4 to 5 weeks, although the range varies from 4 to 14 weeks (see Table 14 -1). Endogenous IgG production starts at approximately 5 to 6 weeks of age in kittens with colostrum ingestion, whereas production of IgA begins a short time later. IgM slowly increases until approximately 8 weeks of age and then concentrations remain steady. Colostrum-deficient or -deprived kittens have significantly lower IgG than colostrum-fed kittens until 4 weeks of age and then have a higher level of endogenous IgG than colostrum-fed kittens by 8 weeks of age.

Maternal antibody creates the same vaccination challenges for cats as described in dogs. Colostrum-fed kittens have a window between 4 to 14 weeks, in which maternal antibody drops to nonprotective levels; however, it is still high enough to interfere with vaccination and the kitten's response to foreign antigens. Predicting when this window will occur and the precise time to vaccinate will be different in each individual animal, complicating vaccination in kittens. It is also important to know if the animal has received colostrum because vaccination guidelines will differ, depending on colostrum ingestion as the result of differences in immunologic development.

Vaccination for the infectious microorganisms that can affect puppy and kitten survival and well-being and for public health concerns has been of vital importance for disease control. The major problem with vaccination protocols is determining the appropriate time to administer the vaccine to achieve optimal immunization. There are three main obstacles to consider when vaccinating puppies and kittens, including the immature immune system, possible bias toward humoral immunity, and presence of maternal antibodies. Although in-depth research has not been performed specifically in cats and dogs, comparative studies done in humans and mice have observed reduced expression of ligands on APCs and lymphocytes in neonates, resulting in decreased interaction between these cells. The APC and lymphocyte interaction is necessary to stimulate a specific T cell response. Another difference in neonates compared to adults is the late mised animals (immunosuppressive medications, susceptible breeds, concurrent viral or bacterial infections, and nutritional stress).

Over the past decade, there has been a concerted effort to increase the duration of protective immunity while decreasing the adverse effects associated with certain vaccines. The use of vaccines is highest during the first year of life for puppies and kittens. The benefits of vaccine use are listed in Box 14-1. There are also vaccine reactions that may occur after vaccination.

Adverse reactions must always be considered when vaccinating a neonate or adult dog or cat; fortunately the most common side effect is protection against an infectious disease that could cause morbidity or mortality. Numerous vaccinations are given without consequence, but it is important to remember that vaccines are biologic agents and adverse reactions can occur even after undergoing strict testing for safety, efficacy, and purity. Vaccine reactions can occur locally at the injection site or systemically. Systemic effects can range from generalized malaise to hypersensitivity reactions or sometimes neoplasia. The most common side effects include local inflammation at the site of injection and generalized malaise lasting for 1 to 2 days after immunization. However, some localized inflammation can persist for weeks to months.

The type of vaccine, breed, administration guidelines, and immune status can all play roles in whether an animal will have a vaccine reaction. For example, modified live-virus vaccines elicit a stronger antigenic response in the host than killed vaccines and are often very effective. However, in immunocompromised patients or young kittens and puppies, there may be a heightened risk of adverse reactions with these types of vaccines. There are also breed predispositions to vaccine reactions, such as the Akita, Great Dane, American cocker spaniel, dachshund, poodle, Old English sheepdogs, among others, and these predispositions should be considered with immunization. This latter point is worth further explanation. It is known that there are subclinical carriers in the dog and cat populations that are immune from disease but still capable of shedding infectious microorganisms consistently or intermittently such as canine parainfluenza in aerosols and canine parvovirus (CPV)and FCoV in feces (Figure 14-4) . Shedding animals are sources of infections for susceptible animals in the population. These include pregnant animals, young puppies and kittens (<6 months old), and immunocompro- BOX 14-1 Reasons to maintain an active immunization program

In human medicine, there is a lot of attention given to suspected associations between vaccination and autoimmunity. Although not scientifically proved, these concerns should persist until evidence proves otherwise. A possible mechanism of vaccine-associated autoimmunity is epitope mimicry, in which an antigen in a vaccine is similar to a self-antigen, causing the immune response to be directed at an antigen on a population of the animal's cells. Certain types of adjuvant can stimulate different pathways of the immune response and some vaccines may stimulate differentiation of pathogenic lymphocytes that recognize selfantigens. It has been shown that all adult humans have some B and T cell lymphocytes that recognize self-antigens; however, these cells are typically quiescent. With some vaccinations, these cells could become reactive or overreactive, resulting in autoimmunity. Because neonates often have a reduced immune response, it is thought they may be more protected from autoimmune reactions. Further studies need to be performed to confirm vaccine-associated autoimmune reactions and potential consequences in the neonate.

The practice of measuring an immune response to determine infection by using acute and convalescent serology, by IgM serology, or by enzyme-linked immunosorbent assay (ELISA) has been accepted for diagnostic purposes and for assessing Systemic vaccine reactions are often the result of hypersensitivity reactions. Hypersensitivity reactions can include immediate reactions occurring within minutes to hours to more delayed reactions that occur 24 to 72 hours or even 7 to 45 days after vaccination. Hypersensitivity reactions can result from a type I hypersensitivity reaction mediated by IgE resulting in anaphylaxis. Anaphylactic reactions occur within minutes to a few hours after vaccine administration and clinical signs can include edema and pruritus, often seen in the dog, or vomiting and diarrhea in cats. More significant sequelae can occur, including respiratory distress, hypovolemia, and shock. Type II hypersensitivity, which is an autoimmune reaction, is also thought to occur after vaccination in some dogs. This has not been definitively proved; however, immune-mediated thrombocytopenia and anemia have been reported in conjunction with recent immunization. Type III hypersensitivity, or immune complex disease, is another type of reaction that can be seen with some vaccines. A specific example in the dog includes anterior uveitis, which occurs approximately 10 to 21 days after canine adenovirus-1 (CAV-1) vaccination as a result of antibody-antigen complex deposition. The last type of hypersensitivity is type IV hypersensitivity, which is a delayed response resulting in granuloma formation at the site of vaccination. Granulomas can resolve within weeks to months in some animals and are typically seen with adjuvant vaccines. In cats, inflammation can persist sometimes, transitioning from chronic inflammation to a neoplastic process resulting in an injection site sarcoma. Immune assessment antibody profiles are available through most veterinary diagnostic laboratories. Assays that measure the CMI response/T cell responsiveness are currently being developed and will utilize measures to monitor T cell-specific cytokines. vaccine challenge studies for a number of years. With the increased concerns about adverse effects of vaccination, there has been a trend to use antibody titers to specific viral antigens to assess immune competence and in some cases, provide information on protective levels of antibody. This practice has gained acceptance for those breeds of dogs and cats that have adverse effects after vaccination but usually applies to animals over 1 year of age. Antibody titer evaluation has been used more within the first year of life to determine if puppies and kittens are receiving adequate levels of maternal antibody and if they would benefit from a booster at 6 months of age. Antibody (IgG) levels of 1:100 or greater to CDV and CPV are generally regarded as protective against disease.

It is important to recognize that a protective antibody titer does not mean that the dog is not infected or that it is not a subclinical carrier-intermittent shedder. Cats with FPL IgG antibody titers of 1:100 or greater are regarded as protected against disease but that does not mean that the cat is not a subclinical carrier.

Protect individual dog and cat from disease. 2. Protect the majority of animals in the population from disease (kennel/cattery "herd" immunity)

Serve as an immune barrier for zoonotic and emerging infectious diseases

Protect fetus from infection (congenital infections; abortions; stillbirths; and so on)

Decreased shedding of infectious agents from subclinical carriers to susceptible animals

Protect puppies and kittens from disease by colostral immunity and lactogenic (early milk) immunity